Maternal Tdap Vaccination Protects Youngest Infants From Pertussis

WEDNESDAY, Feb. 8, 2023 (HealthDay News) — Introduction of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination during pregnancy can protect the youngest infants from pertussis, according to a study published online Feb. 6 in JAMA Pediatrics.

Tami H. Skoff, from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues calculated and compared pertussis incidence rates in the pre-maternal Tdap vaccination period (2000 to 2010) and the post-maternal Tdap vaccination period (2012 to 2019) for infants younger than 2 months (target group of maternal vaccination) and infants age 6 to less than 12 months (comparison group).

The researchers found that in the pre-maternal Tdap vaccination period, annual pertussis incidence did not change among infants aged younger than 2 months and increased slightly among older infants, with no change in the difference in incidence seen between the two age groups. In the post-maternal Tdap vaccination period, there was a decrease in incidence observed among infants younger than 2 months (slope, −14.53 per 100,000 infants per year), while no change was seen for older infants (slope, 1.42 per 100,000 infants per year). During the post-maternal Tdap vaccination period, the incidence rate difference between the two age groups decreased significantly (slope, −14.43 per 100,000 infants per year). Between the pre- and post-maternal Tdap vaccination periods, pertussis incidence rate differences were significantly different (slope difference, −14.51 per 100,000 infants per year).

“Our data suggest that maternal Tdap vaccination is associated with a reduction in disease burden among the youngest and most vulnerable age group (<2 months),” the authors write.

Abstract/Full Text (subscription or payment may be required)